News
Actio Biosciences has closed a Series B financing round, raising $66m for advancing the genetics-driven small molecule ...
In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?
Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...
This was the stock's second consecutive day of losses.
Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...
Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
This trial evaluated the safety and efficacy of the combination of Regeneron’s Lynozyfic (linvoseltamab), a B-cell maturation ...
Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as expected in the third quarter of this year.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback